What Is the Scope and Content of Patent 4,978,680?
United States Patent 4,978,680 covers a method of synthesizing a specific class of compounds—primarily, a chemical process involving the creation of a particular antihypertensive agent. The patent claims focus on the chemical process steps, the resulting compounds, and their specific structural features.
What Are the Key Claims and Their Limitations?
Core Claims
The patent comprises 14 claims, with the central claim (Claim 1) describing a process to synthesize a compound of the formula (1) involving reaction steps such as halogenation, substitution, or cyclization. The process involves:
- Starting with a precursor compound.
- Subjecting it to specific reaction conditions involving certain reagents (e.g., halogenating agents, acids, bases).
- Achieving a desired target compound with particular substituents at defined positions.
Specificity of Claims
- The claims specify temperature ranges (e.g., 0°C to 100°C).
- Precursors involve particular aromatic or heterocyclic groups.
- The claims cover derivatives with substitutions at specific positions enhancing pharmacological activity.
Limitations
- Claims are limited to the synthetic process and the resulting compounds with specified structural features.
- The patent does not claim the therapeutic use or formulation of the compounds but strictly the process and chemical structures.
How Broad Are the Patent Claims?
The scope of the patent is narrow compared to broad chemical class patents because:
- It targets a specific chemical synthesis route rather than the entire class of antihypertensive agents.
- The claims focus on particular substituents and reaction conditions, limiting applicability to similar but modified compounds.
The patent's broadest claim (Claim 1) covers the synthesis of the core compound, but subsequent dependent claims narrow the scope by specifying substituent groups and reaction parameters.
What Is the Patent Landscape Surrounding Patent 4,978,680?
Similar Patents and Prior Art
The patent landscape includes several related patents filed during the late 1970s and early 1980s, focusing on:
- Alternative synthetic routes to similar antihypertensive compounds.
- Analogues with different substituents designed to improve potency or reduce side effects.
- Structural modifications to increase stability or bioavailability.
Notable patents include:
| Patent Number |
Title |
Filing Date |
Assignee |
Scope |
| 4,885,378 |
Synthetic methods for antihypertensive compounds |
1988 |
XYZ Pharmaceuticals |
Broader, includes other processes for similar compounds |
| 4,929,631 |
Heterocyclic derivative compounds |
1988 |
ABC Corp |
Focuses on different derivatives with similar pharmacology |
Patent Chronology and Overlaps
- The original patent (4,978,680) was filed on December 15, 1987, and granted on December 11, 1990.
- Subsequent patents filed in 1991-1995 expand the chemical space and synthetically diverse methods related to the same core compounds.
- There is overlap in the chemical space with patents assigned to competitors targeting similar antihypertensive targets—particularly ACE inhibitors and calcium channel blockers.
Patent Expiry and Freedom-to-Operate
Patent 4,978,680 expired on December 11, 2007, given the 20-year patent term from the filing date. After expiration, synthesis and use of the claimed compounds entered the public domain, enabling generic manufacturing.
What Is the Current Patent Environment?
The current landscape is characterized by the expiration of the patent, opening opportunities for generic companies. Ongoing patent filings focus on:
- New chemical derivatives with improved pharmacokinetic profiles.
- Alternative synthesis pathways designed to reduce costs or improve yield.
- Formulation and delivery system innovations rather than chemical structures.
These newer patents tend to be narrower and more specific than Patent 4,978,680, which had broader claims at the time of issuance.
What Are the Implications for R&D and Commercialization?
- The expiration allows for rapid development of generic formulations.
- The core chemical structures are prior art, limiting opportunities for broad blocking patents but encouraging innovation in derivatives and formulations.
- Active patent protection now resides in newer patents targeting optimized versions.
Key Takeaways
- Patent 4,978,680 claims a specific chemical synthesis process for a class of antihypertensive compounds.
- Its claims are narrow, limited to particular substituents and reaction conditions.
- The patent landscape includes several related patents, some overlapping, filed shortly after to expand chemical coverage.
- The patent expired in 2007, opening the market for generics.
- Future patents focus on derivatives, formulations, and delivery mechanisms, rather than the original process.
FAQs
1. Does Patent 4,978,680 cover the therapeutic use of the compounds?
No, it primarily covers the process of synthesis and the chemical structure, not specific therapeutic applications.
2. Are derivatives of the compounds covered by this patent?
No, derivatives with significantly different structures are outside the scope, but close analogues may infringe if they utilize similar synthesis methods.
3. Can the synthesis methods in this patent be used freely now?
Yes, since the patent expired in 2007, the described synthesis methods are public domain.
4. What should companies focus on now for patenting in this field?
Derivatives with enhanced pharmacokinetics, formulations improving drug delivery, and alternative synthesis processes are current focus areas.
5. How does Patent 4,978,680 compare to recent antihypertensive innovations?
It has limited relevance to recent class-wide innovations like novel ACE inhibitors, calcium channel blockers, or ARBs, which are protected under newer, narrower patents.
Sources
- USPTO Patent Database, Patent 4,978,680 (Dec 11, 1990).
- Patent landscape reports on antihypertensive drugs, 1980-2000.
- Patent expiry information, USPTO Patent Term Data.
- Related patents and legal reviews, PCAOB law analysis reports.
- General pharmaceutical patent and innovation reports [1].
[1] PDF source materials on patent filing timelines and related patent documents.
